Long-term outcomes after transcatheter aortic valve replacement

Area of Science:

• Cardiology
• Interventional Cardiology
• Cardiac Surgery

Background:

• Transcatheter aortic valve replacement (TAVR) is increasingly used for severe aortic stenosis (AS), surpassing surgical aortic valve replacement (SAVR).
• Understanding the long-term efficacy and safety of TAVR, especially in younger and lower-risk populations, is essential for lifelong management of AS.

Purpose of the Study:

• To evaluate and compare the long-term outcomes of TAVR versus SAVR in patients with severe AS.
• To synthesize data from recent randomized trials reporting outcomes beyond five years.

Main Methods:

• Analysis of three randomized controlled trials (NOTION, PARTNER 3, Evolut Low-Risk) comparing TAVR and SAVR.
• Inclusion of primary composite outcomes (all-cause mortality, stroke, MI, rehospitalization) and secondary outcomes (reintervention rates) reported beyond 5 years.

Main Results:

• Primary composite outcomes were similar between TAVR and SAVR across the analyzed trials.
• Reintervention rates were comparable in NOTION and PARTNER 3, but higher for TAVR in the Evolut Low-Risk trial.
• Limitations include small cohort sizes, use of early-generation devices, and limited follow-up beyond 7 years in some trials.

Conclusions:

• TAVR demonstrates comparable long-term safety and efficacy to SAVR for severe AS based on current evidence up to 10 years.
• Careful patient selection remains paramount for achieving optimal long-term outcomes with TAVR.
• Further long-term data are needed, particularly for newer TAVR generations and younger patient cohorts.